started · updated
Novo Nordisk unveils 2030 growth strategy amid share price decline
Novo Nordisk unveiled its strategic roadmap during a Capital Markets Day in London, aiming to diversify its portfolio and maintain growth amid increasing competition in the obesity market. CEO Mike Doustdar announced plans to launch more than five multi-blockbuster drugs by 2030 and targets over 150 billion Danish kroner in pipeline sales by 2035. To address looming patent expirations for semaglutide in the early 2030s, the company is expanding its research into cardiovascular, liver, and endocrine diseases.
The company also emphasized a shift toward oral therapies, aiming to increase production of oral obesity treatments tenfold to serve 15 million patients by the end of the decade. Recent strategic moves include a partnership with Orbis Medicines for oral macrocycle therapeutics and the acquisition of early-stage programs from Kallyope.
Despite these ambitious targets, Novo Nordisk shares fell as much as 9% in Copenhagen. Investors expressed concern over the company’s ability to regain its market lead from Eli Lilly and sought more concrete details regarding near-term turnaround efforts and margin stability.
Entities
Eli Lilly · Eli Lilly & Co · Federal Trade Commission · Kallyope · Latham & Watkins · Metsera, Inc. · Mike Doustdar · Novo Nordisk · Orbis Medicines · Pfizer Inc.
Claims
What the coverage asserts, and how many sources carry each claim.
- [● 5 SOURCES] CEO Mike Doustdar stated the company needs to work harder to drive growth. nemosnewsnetwork.com · www.finanzen.net · www.finanznachrichten.de · www.cnnbrasil.com.br · world-today-journal.com
- [○ 1 SOURCE] Novo Nordisk entered a partnership with Orbis Medicines worth up to $1.4 billion. legaldesire.com
- [● 8 SOURCES] Novo Nordisk shares fell by as much as 7% to 9% in Copenhagen following the Capital Markets Day. nemosnewsnetwork.com · www.cnnbrasil.com.br · world-today-journal.com · www.focus.de · www.spacemoney.com.br · +3 more
- [● 8 SOURCES] The company targets over 150 billion Danish kroner in pipeline sales by 2035. www.cnnbrasil.com.br · world-today-journal.com · www.focus.de · nordiclifescience.org · www.spacemoney.com.br · +3 more
- [● 4 SOURCES] Novo Nordisk plans to reach more than 60 million patients globally by 2030. www.cnnbrasil.com.br · www.focus.de · nordiclifescience.org · www.sharedeals.de
- [● 6 SOURCES] Semaglutide patent protection is expected to expire in the early 2030s. nemosnewsnetwork.com · www.cnnbrasil.com.br · world-today-journal.com · www.focus.de · www.finanznachrichten.de · +1 more
- [● 10 SOURCES] Novo Nordisk aims to launch more than five multi-blockbuster drugs by 2030. www.cnnbrasil.com.br · world-today-journal.com · www.focus.de · nordiclifescience.org · www.spacemoney.com.br · +5 more
- [● 4 SOURCES] The company intends to increase production of oral obesity therapies tenfold by the end of the decade. www.cnnbrasil.com.br · www.focus.de · nordiclifescience.org · www.spacemoney.com.br